Bullish Case: ALKS sits at $39.08 after a -25.9% ninety-day correction, yet Helium's price forecast is +3.46% with bullish risk 34% above bearish, and calls out-traded puts 72% at 100th-percentile volume. The Helium PDF peaks at $39-40 (density 0.097-0.100) versus market's $39-40, with Helium IV running below market IV at every tenor beyond Oct 17 (47.2% vs 52.6% for Dec; 48.1% vs 52.8% for Feb), implying volatility overpricing that can compress. Early ALKS 7290 ADHD data (19-point symptom reduction at 50mg after two weeks) and a strong cash position support re-rating toward the mid-40s.

Bearish Case: The stock has fallen 15.1% in a month with Helium IV now 5% above market IV — momentum has reversed against the bullish thesis. Near-term Oct 17 market IV of 130% signals acute event risk, and the return surface retains heavy downside mass to -25%. Avadel integration costs, debt burdens, and any alixorexton/Brilliance timeline slip could extend the slide toward $34-35, where put IV (181-307%) shows persistent tail hedging. Mean-reverting price action historically caps bounces.

Potential Outcomes:

1. ~40% Stabilization and drift higher: call-dominated flow and Helium's +3.46% forecast materialize; ALKS ranges $38-43 into the Nov 21 expiry.
2. ~30% Continued digestion: mean reversion holds price $35-39 as Avadel integration costs weigh; IV compresses gradually.
3. ~20% Renewed downside: integration/debt or pipeline slip drives a test of $34-35, where extreme put IV (180-300%) suggests hedged tail fear.
4. ~10% Positive catalyst (ALKS 7290 data expansion, Brilliance progress, or M&A interest) triggers IV crush and a fast move toward $45-50.

October 15, 2026